Figure 5.

Phenotype of tumor-associated macrophages/monocytes and NK cells in tumors and spleens of mice treated with chemoimmunotherapy. A, Gating strategy to identify CD11b⁺Ly6G⁻Ly6C⁺MHC II⁻ and CD11b⁺Ly6G⁻Ly6C⁻MHC II⁺ monocytes/macrophages. B, Percentage of CD11b⁺Ly6G⁻ cells of all CD45⁺ cells in spleens (blue) and tumors (red). C and D, Groups refer to the assignment shown in Fig. 4B. Percentages of CD11b⁺Ly6G⁻Ly6C⁺MHC II⁻ and CD11b⁺Ly6G⁻Ly6C⁻MHC II⁺ in spleens (C) and tumors (D). E, Gating strategy to identify DX5⁺CD27⁺CD11b⁻ immature NK cells and DX5⁺CD27⁻CD11b⁺ mature NK cells. F, Percentage DX5⁺ NK cells of all CD45⁺ cells in spleens (blue) and tumors (red). G and H, Percentages of immature NK cells in spleens (G) and tumors (H).